HTHT
APUS

Hemenway Trust Hemenway Trust’s Apimeds Pharmaceuticals US APUS Stock Holding History

Hemenway Trust Hemenway Trust’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$490K Hold
27,400
– – 0.04% 81
2025
Q4 		$449K Buy
27,400
+2,400
+10% +$51.2K 0.03% 87
2025
Q3 		$445K Buy
+25,000
New +$463K 0.03% 88

Other funds holding APUS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hemenway Trust Hemenway Trust's APUS Position: Q1 2026 in Review

Hemenway Trust Hemenway Trust held its Apimeds Pharmaceuticals US (APUS) position steady in Q1 2026 at 27,400 shares worth $490K. The position accounts for 0.04% of the portfolio, ranked #81.

Hemenway Trust Hemenway Trust first reported a position in APUS in Q3 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold APUS as of Q1 2026.

  • Hemenway Trust Hemenway Trust held 27,400 shares of Apimeds Pharmaceuticals US worth $490K as of Q1 2026.
  • Hemenway Trust Hemenway Trust left its Apimeds Pharmaceuticals US share count unchanged in Q1 2026.
  • Apimeds Pharmaceuticals US made up 0.04% of Hemenway Trust Hemenway Trust's portfolio in Q1 2026, its #81 holding.
  • Hemenway Trust Hemenway Trust first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and has held it in 3 quarters since.
  • 6 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q1 2026.

Based on Hemenway Trust Hemenway Trust's 13F filing for Q1 2026, filed 7 May 2026.